VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,330,861 | +2.7% | 8,284,246 | +0.6% | 0.01% | 0.0% |
| Q2 2023 | $411,324,518 | +68.0% | 8,236,374 | +26.1% | 0.01% | +66.7% |
| Q1 2023 | $244,831,203 | -22.8% | 6,532,316 | -1.2% | 0.01% | -33.3% |
| Q4 2022 | $317,125,284 | +196.8% | 6,613,666 | +48.6% | 0.01% | +200.0% |
| Q3 2022 | $106,851,000 | +24.1% | 4,452,145 | +12.5% | 0.00% | +50.0% |
| Q2 2022 | $86,081,000 | -1.8% | 3,955,918 | +9.0% | 0.00% | 0.0% |
| Q1 2022 | $87,649,000 | +17.5% | 3,629,364 | +15.8% | 0.00% | 0.0% |
| Q4 2021 | $74,565,000 | -3.4% | 3,134,286 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $77,224,000 | +20.4% | 3,043,882 | +6.9% | 0.00% | 0.0% |
| Q2 2021 | $64,123,000 | +17.2% | 2,848,644 | +2.8% | 0.00% | +100.0% |
| Q1 2021 | $54,734,000 | +42.1% | 2,771,314 | +91.2% | 0.00% | 0.0% |
| Q4 2020 | $38,510,000 | -42.4% | 1,449,377 | +7.1% | 0.00% | -50.0% |
| Q3 2020 | $66,802,000 | +6946.6% | 1,352,820 | +4409.4% | 0.00% | – |
| Q2 2020 | $948,000 | – | 30,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |